Small Molecule Inhibitor of CBFβ-RUNX Binding for RUNX Transcription Factor Driven Cancers

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Transcription factors, like core binding factor (CBF), are increasingly recognized as potential drug targets for cancer therapy.
• CBF, a heterodimer of RUNX proteins and CBFβ, is crucial for cell functions and frequently mutated in leukemia.
• RUNX proteins also play significant roles in epithelial cancers, indicating broad therapeutic potential.

Purpose of the Study:

• To develop small molecules that inhibit the interaction between CBFβ and RUNX proteins.
• To investigate the efficacy of these inhibitors in preclinical cancer models.

Main Methods:

• Development of small molecule inhibitors targeting CBFβ.
• Assays to measure the impact of inhibitors on RUNX binding to DNA and gene expression.
• Testing inhibitor efficacy in leukemia and basal-like breast cancer cell lines.

Main Results:

• Small molecules successfully inhibited CBFβ binding to RUNX proteins.
• Inhibitors reduced RUNX1 binding to target genes and altered gene expression.
• Treatment with inhibitors affected cancer cell survival and differentiation.
• Demonstrated efficacy against leukemia and triple-negative breast cancer cells.

Conclusions:

• Targeting the RUNX-CBFβ pathway with small molecule inhibitors is a viable strategy for cancer treatment.
• These inhibitors provide valuable tools for further research into RUNX transcription factor function in various cancers.
• This approach offers potential for novel mechanisms to overcome chemo-resistance and cancer stem cell properties.